It has been a bumpy road, but the phase IIa trial in the debilitating, rare eating disorder Prader-Willi Syndrome (PWS) is now completed, following results from the open-label extension parts. Overall, we argue that the phase IIa has provided important data on tesomet and that the data package strongly supports continuing development into a ph IIb/III (pivotal) program in PWS.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se